Advanced Non Small Cell Lung Cancer Clinical Trial
Official title:
Almonertinib Plus Microwave Ablation Versus Almonertinib in Previously Untreated，Advanced Non-small Cell Lung Cancer, a Randomized，Controlled，Phase II Clinical Trial
Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial.
Almonertinib, as a third-generation EGFR-TKI, has been used for the treatment of advanced non small cell lung cancer. How to improve the progression free survival in advance was a challenge. Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone. So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized, controlled, phase II clinical trial. Patients were assigned into two groups.In the experiment group, patients were treated with both Almonertinib and microwave ablation. In the control group, patients were treated with Almonertinib alone. The primary end point was progression free survival. Second endpoints included overall survival and safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03326752 -
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
|
Phase 1 | |
| Completed |
NCT02157883 -
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
|
Phase 1 | |
| Completed |
NCT00072631 -
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT02163733 -
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06107374 -
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
|
Phase 2 | |
| Completed |
NCT01802632 -
AZD9291 First Time In Patients Ascending Dose Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06406166 -
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
|
N/A | |
| Terminated |
NCT04785365 -
Long-Term Follow-Up Study of Patients Receiving ATL001
|
Phase 2 | |
| Recruiting |
NCT04032847 -
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT01631136 -
Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04239443 -
Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
|
Phase 2 | |
| Completed |
NCT03452150 -
D-0316 First Time in Patients Ascending Dose Study
|
Phase 1 | |
| Completed |
NCT04144608 -
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03652857 -
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03351361 -
Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients
|
Phase 3 | |
| Completed |
NCT02407327 -
Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
|
||
| Active, not recruiting |
NCT02143466 -
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
|
Phase 1 | |
| Recruiting |
NCT05004974 -
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05777603 -
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT04886401 -
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC
|